Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference

Posted: April 19, 2022 at 1:53 am

WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company will deliver multiple data presentations on sulbactam-durlobactam (SUL-DUR) at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual conference, to be held April 23-26, 2022 in Lisbon, Portugal.

Excerpt from:
Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference

Related Posts